藥明生物上半年經調整純利同比增163% 再次超額完成業績目標
格隆匯8月23日丨藥明生物公佈業績顯示,2021年上半年收益同比增126.7%,達人民幣44.07億元;同時集團毛利亦同比增191.7%至人民幣22.97億元;公司擁有人應佔純利18.42億元,同比增150.3%;公司擁有人應佔經調整純利17.69億元,同比增163%。
公告稱,集團再次超額完成業績目標。憑藉其行業領先的賦能平臺,集團繼續成功實施“贏得分子”策略,爲加速及轉變生物藥(特別是COVID-19藥物及疫苗)的發現、開發及生產提供端到端解決方案。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.